The findings of this cost-effectiveness analysis by Hafeez et al 1 are highly significant because they address one of the most important unresolved questions in contemporary venous disease management: how does one optimize outcomes for patients with iliofemoral deep vein thrombosis (IFDVT) while maintaining responsible health care spending in an increasingly financially constrained environment?
← all excerpts
Clot value: Why mechanical thrombectomy may be the smartest investment in iliofemoral deep vein thrombosis care.
1
—
—